Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Hematol ; 103(6): 1931-1940, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38478023

ABSTRACT

Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence is scant. The Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera (RAMP) prospective multicenter study (NCT06078319) included 189 ruxolitinib-treated patients. Patients completed the Adherence to Refills and Medications Scale (ARMS) and Distress Thermometer and Problem List (DTPL) at the earliest convenience, after registration in the study, and at later timepoints. At week-0, low adherence (ARMS > 14) and high distress (DT ≥ 4) were declared by 49.7% and 40.2% of patients, respectively. The main reason for low adherence was difficult ruxolitinib supply (49%), intentional (4.3%) and unintentional (46.7%) non-take. In multivariable regression analysis, low adherence was associated to male sex (p = 0.001), high distress (p < 0.001), and treatment duration ≥ 1 year (p = 0.03). Over time, rates of low adherence and high distress remained stable, but unintentional non-take decreased from 47.9% to 26.0% at week-48. MF patients with stable high adherence/low distress were more likely to obtain/maintain the spleen response at week-24. Low adherence to ruxolitinib represents an unmet clinical need that require a multifaceted approach, based on reason behind it (patients characteristics and treatment duration). Its recognition may help distinguishing patients who are truly refractory and those in need of therapy optimization.


Subject(s)
Medication Adherence , Nitriles , Polycythemia Vera , Primary Myelofibrosis , Pyrazoles , Pyrimidines , Humans , Primary Myelofibrosis/drug therapy , Pyrimidines/therapeutic use , Pyrazoles/therapeutic use , Male , Polycythemia Vera/drug therapy , Female , Prospective Studies , Aged , Middle Aged , Italy/epidemiology , Medication Adherence/statistics & numerical data , Aged, 80 and over , Adult
2.
Boll Ist Sieroter Milan ; 64(4): 339-42, 1985.
Article in English | MEDLINE | ID: mdl-3000406

ABSTRACT

Anti-HTLV III prevalence has been investigated in serum samples of 638 intravenous drug users collected over May 1981 - March 1985 and stored at -20 degrees C. Separately, in a prospective way, we have studied 68 IV drug abusers (53 Genoese and 15 of Sanremo area) of whom we have collected, at least, one serum specimen for each year, starting with 1981. We have also tested for anti-HTLV III presence serum samples of: 91 subjects of Hospital staff (Infectious Diseases Department and Laboratory workers); 32 workers in Therapeutic Communities for drug users and 24 family contacts of anti-HTLV III positive drug users. And then serum samples of two groups of general population collected for other seroepidemiological investigations in 1982 (256 subjects) and 1984 (538 subjects) were tested. No IV drug user was positive in 1981 whilst from 1982 up to 1984 there was a strong rising of the prevalence of anti-HTLV III positive subjects: 2, 22, and 39 per cent, respectively. The prevalence remained about 40% in the first months of 1985. The investigations carried out also show that HTLV III spread in Sanremo area slightly before than in Genoa and neighbourhood. No subject positive for anti-HTLV III has been detected among the Hospital staff and in workers of Therapeutic communities who have more probability to get in contact with infected subjects or their blood, as well as in the general population. A positive case has been discovered in a family contact (the wife of a positive for anti-HTLV III IV drug user). Some epidemiological and public health questions linked to the situation observed, at present, in Liguria, are discussed.


Subject(s)
Retroviridae Infections/epidemiology , Substance-Related Disorders/complications , Antibodies, Viral/analysis , Deltaretrovirus , Epidemiologic Methods , Female , Humans , Italy , Male , Retroviridae Infections/genetics
3.
Boll Ist Sieroter Milan ; 64(5): 367-70, 1985.
Article in English | MEDLINE | ID: mdl-3004543

ABSTRACT

Prevalence of positive subjects to anti-HTLV III and HBV markers (HBsAg; anti-HBc; anti-HBs) has been studied both among jailed people and wardens of Sanremo Jail. Out of 92 subjects in custody, 11 were anti-HTLV III positive and 44 had acquired HBV infection markers (antigen and/or antibodies). One of the wardens resulted anti-HTLV III positive whilst 14 appeared to have been infected by HBV. All anti-HTLV III positive subjects, but the warden, were intravenous drug users. The study of prevalence was the first step of a perspective monitoring program in Ligurian Jails.


Subject(s)
Acquired Immunodeficiency Syndrome/epidemiology , Hepatitis B/epidemiology , Prisoners , Acquired Immunodeficiency Syndrome/complications , Adult , Antibodies, Viral/analysis , Carrier State/immunology , Deltaretrovirus/immunology , Hepatitis B/complications , Hepatitis B Antibodies/analysis , Humans , Italy , Male , Substance-Related Disorders/complications , Substance-Related Disorders/microbiology
4.
Pathology ; 15(4): 373-8, 1983 Oct.
Article in English | MEDLINE | ID: mdl-6326028

ABSTRACT

Frozen sections and cell cultures of 50 human astrocytomas, fetal and adult human brain were examined for immunofluorescence reactivity with antisera to glial fibrillary acidic protein (GFAP), actin, fibronectin and factor VIII antigen. In frozen tissue sections GFAP expression was restricted to normal and neoplastic astrocytes while fibronectin and factor VIII antigen were localized to blood vessels. In primary cell culture, 80-100% neoplastic astrocytes expressed GFAP but not fibronectin or factor VIII antigen while actin was present as diffuse cytoplasmic staining of the cell body and cell processes. By the 5th-6th passage in vitro, GFAP immunoreactivity was lost while fibronectin and actin cables were prominently expressed. Factor VIII antigen remained negative throughout serial subculture. In double fluorochrome experiments, GFAP positive cells did not express fibronectin or actin cables, while GFAP negative cells expressed fibronectin and had prominent actin cables. Our results suggest a change in population of astrocytoma cells with increasing passage in vitro, reflecting either an overgrowth of tumour glioblasts or dedifferentiation of tumour astrocytes.


Subject(s)
Actins/analysis , Antigens/analysis , Astrocytoma/analysis , Brain Chemistry , Brain Neoplasms/analysis , Factor VIII/immunology , Fibronectins/analysis , Glioblastoma/analysis , Intermediate Filament Proteins/analysis , Astrocytoma/pathology , Brain , Brain Neoplasms/pathology , Cell Line , Cells, Cultured , Factor VIII/analysis , Fetus/analysis , Fluorescent Antibody Technique , Frozen Sections , Glial Fibrillary Acidic Protein , Glioblastoma/pathology , Humans , von Willebrand Factor
SELECTION OF CITATIONS
SEARCH DETAIL
...